Lenacapavir rollout in South Africa: what HIV prevention looks like in 2026
South Africa has launched a national rollout of lenacapavir, a twice-yearly HIV prevention injection. Over 55,000 people initiated by September 2026. Here is what it is, who can get it, and why it matters.
Read article →Latest
View all →First new herpes treatment in decades moves closer to approval
Pritelivir received FDA priority review. It showed better lesion healing than standard antivirals in Phase 3 trials.
HIV vaccine research hits a milestone
A vaccine candidate produced broadly protective HIV antibodies in every vaccinated animal. Published in Nature, April 2026.
Cancer drug venetoclax shows promise for shrinking the HIV reservoir
Emory University researchers found the leukaemia drug reduced the SIV reservoir in nonhuman primates.
Long-acting HIV treatment in South Africa
From monthly injections to twice-yearly shots — what's available now and what's coming.
HIV disclosure and the law in South Africa
Proposed changes could criminalize non-disclosure to sexual partners. Here is what the debate is about.
HIV, stigma, and mental health
New research shows HIV-related stigma is associated with higher suicidality. What the data shows, and where to get help.
Targeted HIV drug resistance testing moves into routine care
Wits University's ITREMA-2 study cuts lab monitoring costs by 23%. Adopted by the National Department of Health.
Trump aid cuts risk Africa HIV gains
The chief science officer for PEPFAR resigned, warning that aid cuts risk reversing two decades of HIV progress.
HIV cure research: closer to remission, not yet a universal cure
Spanish researchers are narrowing the distance between laboratory promise and clinical reality.
Haven reaches 1,200 users in South Africa
500 people became 1,200. Here is what we have learned about building a stigma-free app for the HIV+ community.